Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

Keyphrases

• Phase II Study 100%
• Fallopian Tube 100%
• Bevacizumab 100%
• Primary Peritoneal Cancer 100%
• Pemetrexed 100%
• Progression-free Survival 60%
• Epithelial Ovarian Cancer 60%
• Platinum Sensitivity 40%
• Response Rate 20%
• Hematological Malignancies 20%
• Anemia 20%
• Neutropenia 20%
• Overall Survival 20%
• Median Overall Survival 20%
• Median Progression-free Survival 20%
• Nonhematologic 20%
• Complete Response 20%
• Partial Response 20%
• Hematotoxicity 20%
• Thrombocytopenia 20%
• Gastrointestinal 20%
• Prior Chemotherapy 20%
• Taxanes 20%
• Stable Disease 20%
• Progressive Disease 20%
• Metabolic 20%
• Chemotherapy Regimen 20%
• Leukopenia 20%
• Following Response 20%
• Treatment Cycle 20%
• 0-complete 20%
• Platinum-free Interval 20%

Medicine and Dentistry

• Bevacizumab 100%
• Primary Peritoneal Cancer 100%
• Pemetrexed 100%
• Fallopian Tube 100%
• Progression Free Survival 80%
• Krukenberg Tumor 60%
• Overall Survival 40%
• Health Care Cost 20%
• Neutropenia 20%
• Anemia 20%
• Hematologic Malignancy 20%
• Patient History of Chemotherapy 20%
• Progressive Disease 20%
• Thrombocytopenia 20%
• Leukopenia 20%
• Chemotherapy 20%
• Diseases 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 100%
• Pemetrexed 100%
• Peritoneum Cancer 100%
• Progression Free Survival 80%
• Ovary Carcinoma 60%
• Overall Survival 40%
• Diseases 40%
• Hematologic Malignancy 20%
• Anemia 20%
• Neutropenia 20%
• Chemotherapy 20%
• Thrombocytopenia 20%
• Patient History of Chemotherapy 20%
• Leukopenia 20%
• Taxane 20%